322 related articles for article (PubMed ID: 35462428)
1. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
Ständer S; Bhatia N; Gooderham MJ; Silverberg JI; Thyssen JP; Biswas P; DiBonaventura M; Romero W; Farooqui SA
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1308-1317. PubMed ID: 35462428
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
3. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
4. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
7. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
Cork MJ; McMichael A; Teng J; Valdez H; Rojo R; Chan G; Zhang F; Myers DE; DiBonaventura M
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):422-433. PubMed ID: 34743361
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.
Schmid-Grendelmeier P; Gooderham MJ; Hartmann K; Konstantinou GN; Fellmann M; Koulias C; Clibborn C; Biswas P; Brunner PM
Allergy; 2024 Jan; 79(1):174-183. PubMed ID: 37988255
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
Eichenfield LF; Flohr C; Sidbury R; Siegfried E; Szalai Z; Galus R; Yao Z; Takahashi H; Barbarot S; Feeney C; Zhang F; DiBonaventura M; Rojo R; Valdez H; Chan G
JAMA Dermatol; 2021 Oct; 157(10):1165-1173. PubMed ID: 34406366
[TBL] [Abstract][Full Text] [Related]
10. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Johnson S; Farooqui SA; Kerkmann U; Clibborn C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2056-2066. PubMed ID: 37335885
[TBL] [Abstract][Full Text] [Related]
11. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
12. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
[TBL] [Abstract][Full Text] [Related]
13. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type.
Alexis AF; Silverberg JI; Rice ZP; Armstrong AW; Desai SR; Fonacier L; Kabashima K; Biswas P; Cella RR; Chan GL; Levenberg M
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):383-389.e3. PubMed ID: 37949351
[TBL] [Abstract][Full Text] [Related]
14. Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Farooqui SA; Kerkmann U; Clibborn C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2047-2055. PubMed ID: 37319109
[TBL] [Abstract][Full Text] [Related]
15. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
[TBL] [Abstract][Full Text] [Related]
16. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
Reich K; Lio PA; Bissonnette R; Alexis AF; Lebwohl MG; Pink AE; Kabashima K; Boguniewicz M; Nowicki RJ; Valdez H; Zhang F; DiBonaventura M; Cameron MC; Clibborn C
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3228-3237.e2. PubMed ID: 36108923
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
[TBL] [Abstract][Full Text] [Related]
18. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
[TBL] [Abstract][Full Text] [Related]
19. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
20. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
